Clinical management of atopic dermatitis: Practical highlights and updates from the atopic dermatitis practice parameter 2012

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 4, 2014, Pages 361-369

  Lio, Peter A ^a   Lee, Margaret ^b   LeBovidge, Jennifer ^b   Timmons, Karol G ^b   Schneider, Lynda ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

AD; ADPP; Atopic dermatitis; Eczema; FLG; Guidelines; Moisturizers; Topical therapy; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; FLUTICASONE; PIMECROLIMUS; TACROLIMUS; VITAMIN D;

ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; BANDAGE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ECZEMA AREA AND SEVERITY INDEX; HUMAN; HYDRATION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; NONSENSE MUTATION; PATIENT ORIENTED ECZEMA MEASURE SCALE; PRACTICE GUIDELINE; PRURITUS; QUALITY OF LIFE; RATING SCALE; REVIEW; SAFETY; SCORING ATOPIC DERMATITIS INDEX; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN HYDRATION; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT INDICATION; VITAMIN SUPPLEMENTATION; WET DRESSING; ANIMAL; DERMATITIS, ATOPIC; DESENSITIZATION; EVIDENCE BASED MEDICINE; PATIENT EDUCATION; PROCEDURES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANIMALS; CALCINEURIN INHIBITORS; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; EVIDENCE-BASED MEDICINE; HISTAMINE ANTAGONISTS; HUMANS; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 84904054172     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.02.015     Document Type: Review

References (102)

1. Schneider L., Tilles S., Lio P., Boguniewicz M., Beck L., LeBovidge J., et al. Atopic dermatitis: a practice parameter update 2012. JAllergy Clin Immunol 2013, 131:295-299.e1-27.
2. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
3. Kim B.E., Leung D.Y., Boguniewicz M., Howell M.D. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008, 126:332-337.
4. Pellerin L., Henry J., Hsu C.Y., Balica S., Jean-Decoster C., Mechin M.C., et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. JAllergy Clin Immunol 2013, 131:1094-1102.
5. Hubiche T., Ged C., Benard A., Leaute-Labreze C., McElreavey K., de Verneuil H., et al. Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort. Acta Derm Venereol 2007, 87:499-505.
6. Sator P.G., Schmidt J.B., Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. JAm Acad Dermatol 2003, 48:352-358.
7. Saunders S.P., Goh C.S., Brown S.J., Palmer C.N., Porter R.M., Cole C., et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. JAllergy Clin Immunol 2013, 132:1121-1129.
8. De Benedetto A., Rafaels N.M., McGirt L.Y., Ivanov A.I., Georas S.N., Cheadle C., et al. Tight junction defects in patients with atopic dermatitis. JAllergy Clin Immunol 2011, 127:773-786.e1-7.
9. Thyssen J.P., Carlsen B.C., Bisgaard H., Giwercman C., Johansen J.D., Linneberg A., et al. Individuals who are homozygous for the 2282del4 and R501X filaggrin null mutations do not always develop dermatitis and complete long-term remission is possible. JEur Acad Dermatol Venereol 2012, 26:386-389.
10. Brandt E.B., Sivaprasad U. Th2 cytokines and atopic dermatitis. JClin Cell Immunol 2011, 2. pii 110.
11. Onoue A., Kabashima K., Kobayashi M., Mori T., Tokura Y. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp Dermatol 2009, 18:1036-1043.
12. Beck L.A., Leung D.Y. Allergen sensitization through the skin induces systemic allergic responses. JAllergy Clin Immunol 2000, 106(Suppl):S258-S263.
13. Eyerich S., Eyerich K., Pennino D., Carbone T., Nasorri F., Pallotta S., et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. JClin Invest 2009, 119:3573-3585.
14. Nograles K.E., Zaba L.C., Shemer A., Fuentes-Duculan J., Cardinale I., Kikuchi T., et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. JAllergy Clin Immunol 2009, 123:1244-1252.e2.
15. Fujita H., Nograles K.E., Kikuchi T., Gonzalez J., Carucci J.A., Krueger J.G. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009, 106:21795-21800.
16. Gittler J.K., Shemer A., Suarez-Farinas M., Fuentes-Duculan J., Gulewicz K.J., Wang C.Q., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. JAllergy Clin Immunol 2012, 130:1344-1354.
17. Beck L.A., Boguniewicz M., Hata T., Schneider L.C., Hanifin J., Gallo R., et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. JAllergy Clin Immunol 2009, 124:260-269. 269.e1-7.
18. Gao P.S., Rafaels N.M., Hand T., Murray T., Boguniewicz M., Hata T., et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater riskfor eczema herpeticum. JAllergy Clin Immunol 2009, 124:507-513. 513.e1-7.
19. Belderbos M.E., Knol E.F., Houben M.L., van Bleek G.M., Wilbrink B., Kimpen J.L., et al. Low neonatal Toll-like receptor 4-mediated interleukin-10 production is associated with subsequent atopic dermatitis. Clin Exp Allergy 2012, 42:66-75.
20. Niebuhr M., Lutat C., Sigel S., Werfel T. Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy 2009, 64:1580-1587.
21. Brandt E.B., Gibson A.M., Bass S., Rydyznski C., Khurana Hershey G.K. Exacerbation of allergen-induced eczema in TLR4- and TRIF-deficient mice. JImmunol 2013, 191:3519-3525.
22. Wollenberg A., Rawer H.C., Schauber J. Innate immunity in atopic dermatitis. Clin Rev Allergy Immunol 2011, 41:272-281.
23. Gao P.S., Leung D.Y., Rafaels N.M., Boguniewicz M., Hand T., Gao L., et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. JInvest Dermatol 2012, 132:650-657.
24. Ikoma A., Rukwied R., Stander S., Steinhoff M., Miyachi Y., Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003, 139:1455-1458.
25. Tobin D., Nabarro G., Baart de la Faille H., van Vloten W.A., van der Putte S.C., Schuurman H.J. Increased number of immunoreactive nerve fibers in atopic dermatitis. JAllergy Clin Immunol 1992, 90:613-622.
26. Wilson S.R., The L., Batia L.M., Beattie K., Katibah G.E., McClain S.P., et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013, 155:285-295.
27. Mishra S.K., Hoon M.A. The cells and circuitry for itch responses in mice. Science 2013, 340:968-971.
28. Tran B.W., Papoiu A.D., Russoniello C.V., Wang H., Patel T.S., Chan Y.H., et al. Effect of itch, scratching and mental stress on autonomic nervous system function in atopic dermatitis. Acta Derm Venereol 2010, 90:354-361.
29. Eichenfield L.F., Hanifin J.M., Luger T.A., Stevens S.R., Pride H.B. Consensus conference on pediatric atopic dermatitis. JAm Acad Dermatol 2003, 49:1088-1095.
30. Eichenfield L.F., Tom W.L., Chamlin S.L., Feldman S.R., Hanifin J.M., Simpson E.L., et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. JAm Acad Dermatol 2014, 70:338-351.
31. Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980, 92:44-47.
32. Rehal B., Armstrong A.W. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011, 6:e17520.
33. Stalder J.F., Barbarot S., Wollenberg A., Holm E.A., De Raeve L., Seidenari S., et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy 2011, 66:1114-1121.
34. Brenninkmeijer E.E., Schram M.E., Leeflang M.M., Bos J.D., Spuls P.I. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol 2008, 158:754-765.
35. Brenninkmeijer E.E., Spuls P.I., Legierse C.M., Lindeboom R., Smitt J.H., Bos J.D. Clinical differences between atopic and atopiform dermatitis. JAm Acad Dermatol 2008, 58:407-414.
36. Suarez-Farinas M., Dhingra N., Gittler J., Shemer A., Cardinale I., de Guzman Strong C., et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. JAllergy Clin Immunol 2013, 132:361-370.
37. Ballardini N., Kull I., Soderhall C., Lilja G., Wickman M., Wahlgren C.F. Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort. Br J Dermatol 2013, 168:588-594.
38. Krol A., Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther 2006, 19:73-82.
39. Thyssen J.P., McFadden J.P., Kimber I. The multiple factors affecting the association between atopic dermatitis and contact sensitization. Allergy 2014, 69:28-36.
40. Simpson E.L., Eichenfield L.F., Ellis C.N., Mancini A.J., Paller A.S. Current issues in atopic comorbidities and preventing the atopic march. Semin Cutan Med Surg 2012, 31(Suppl):S6-S9.
41. Hong J., Buddenkotte J., Berger T.G., Steinhoff M. Management of itch in atopic dermatitis. Semin Cutan Med Surg 2011, 30:71-86.
42. Rork J.F., Sheehan W.J., Gaffin J.M., Timmons K.G., Sidbury R., Schneider L.C., et al. Parental response to written eczema action plans in children with eczema. Arch Dermatol 2012, 148:391-392.
43. Shi V.Y., Nanda S., Lee K., Armstrong A.W., Lio P.A. Improving patient education with an eczema action plan: a randomized controlled trial. JAMA Dermatol 2013, 149:481-483.
44. Chiang C., Eichenfield L.F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol 2009, 26:273-278.
45. Gutman A.B., Kligman A.M., Sciacca J., James W.D. Soak and smear: a standard technique revisited. Arch Dermatol 2005, 14:1556-1559.
46. Lee C.H., Chuang H.Y., Shih C.C., Jong S.B., Chang C.H., Yu H.S. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006, 154:1100-1107.
47. Grimalt R., Mengeaud V., Cambazard F. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007, 214:61-67.
48. Msika P., De Belilovsky C., Piccardi N., Chebassier N., Baudouin C., Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol 2008, 25:606-612.
49. Cork M.J., Britton J., Butler L., Young S., Murphy R., Keohane S.G. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003, 149:582-589.
50. Miller D.W., Koch S.B., Yentzer B.A., Clark A.R., O'Neill J.R., Fountain J., et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. JDrugs Dermatol 2011, 10:531-537.
51. Paller A., Eichenfield L.F., Leung D.Y., Stewart D., Appell M. A12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. JAm Acad Dermatol 2001, 44(Suppl):S47-S57.
52. Santer M., Burgess H., Yardley L., Ersser S.J., Lewis-Jones S., Muller I., et al. Managing childhood eczema: qualitative study exploring carers' experiences of barriers and facilitators to treatment adherence. JAdv Nurs 2013, 69:2493-2501.
53. Boguniewicz M., Nicol N., Kelsay K., Leung D.Y. Amultidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg 2008, 27:115-127.
54. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000, 4:1-191.
55. Berth-Jones J., Damstra R.J., Golsch S., Livden J.K., Van Hooteghem O., Allegra F., Parker C.A. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003, 326(7403):1367. Multinational Study Group.
56. Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000, 142:931-936.
57. Zuberbier T., Orlow S.J., Paller A.S., Taieb A., Allen R., Hernanz-Hermosa J.M., et al. Patient perspectives on the management of atopic dermatitis. JAllergy Clin Immunol 2006, 118:226-232.
58. Wollenberg A., Sharma S., von Bubnoff D., Geiger E., Haberstok J., Bieber T. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. JAllergy Clin Immunol 2001, 107:519-525.
59. Papp K.A., Breuer K., Meurer M., Ortonne J.P., Potter P.C., de Prost Y., et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. JAm Acad Dermatol 2005, 52:247-253.
60. Frankel H.C., Qureshi A.A. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012, 13:113-123.
61. Reitamo S., Rustin M., Ruzicka T., Cambazard F., Kalimo K., Friedmann P.S., et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. JAllergy Clin Immunol 2002, 109:547-555.
62. Hauk P.J., Leung D.Y. Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?. JAllergy Clin Immunol 2001, 107:391-392.
63. Schmitt J., von Kobyletzki L., Svensson A., Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011, 164:415-428.
64. Arellano F.M., Wentworth C.E., Arana A., Fernandez C., Paul C.F. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. JInvest Dermatol 2007, 127:808-816.
65. Klein P.A., Clark R.A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999, 135:1522-1525.
66. Simons F.E. Prevention of acute urticaria in young children with atopic dermatitis. JAllergy Clin Immunol 2001, 107:703-706.
67. Sidbury R.S.A., Thadhani R.I., Camargo C.A. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol 2008, 159:245-247.
68. Peroni D.G., Piacentini G.L., Cametti E., Chinellato I., Boner A.L. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011, 164:1078-1082.
69. Mutgi K., Koo J. Update on the role of systemic vitamin D in atopic dermatitis. Pediatr Dermatol 2013, 30:303-307.
70. Feily A., Namazi M.R. Vitamin A+ D ointment is not an appropriate emollient for atopic dermatitis. Dermatitis 2010, 21:174-175.
71. Frosch P.J., Rustemeyer T. Contact allergy to calcipotriol does exist. Report of an unequivocal case and review of the literature. Contact Dermatitis 1999, 40:66-71.
72. Nakamura Y., Oscherwitz J., Cease K.B., Chan S.M., Munoz-Planillo R., Hasegawa M., et al. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 2013, 503:397-401.
73. Bath-Hextall F.J., Birnie A.J., Ravenscroft J.C., Williams H.C. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol 2010, 163:12-26.
74. Huang J.T., Abrams M., Tlougan B., Rademaker A., Paller A.S. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009, 123:e808-e814.
75. Komata T., Soderstrom L., Borres M.P., Tachimoto H., Ebisawa M. The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age. JAllergy Clin Immunol 2007, 119:1272-1274.
76. Lee J.H., Lee S.J., Kim D., Bang D. The effect of wet-wrap dressing on epidermal barrier in patients with atopic dermatitis. JEur Acad Dermatol Venereol 2007, 21:1360-1368.
77. Devillers A.C., Oranje A.P. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006, 154:579-585.
78. Bendsoe N., Bjornberg A., Asnes H. Itching from wool fibres in atopic dermatitis. Contact Dermatitis 1987, 17:21-22.
79. Wuthrich B., Schmid-Grendelmeier P. The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. JInvestig Allergol Clin Immunol 2003, 13:1-5.
80. Gutgesell C., Heise S., Seubert S., Seubert A., Domhof S., Brunner E., et al. Atopic dermatitis, house-dust mite, and the placebo effect. Allergy 2001, 56:1226-1227.
81. Eigenmann P.A., Sicherer S.H., Borkowski T.A., Cohen B.A., Sampson H.A. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. Pediatrics 1998, 101(3):E8.
82. Thompson M.M., Hanifin J.M. Effective therapy of childhood atopic dermatitis allays food allergy concerns. J Am Acad Dermatol 2005, 53(2 Suppl 2):S214-S219.
83. Bath-Hextall F., Delamere F.M., Williams H.C. Dietary exclusions for improving established atopic eczema in adults and children: systematic review. Allergy 2009, 64:258-264.
84. Boyce J.A., Assa'ad A., Burks A.W., Jones S.M., Sampson H.A., Wood R.A., et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: summary of the NIAID-sponsored expert panel report. JAllergy Clin Immunol 2010, 126:1105-1118.
85. Alanne S., Nermes M., Soderlund R., Laitinen K. Quality of life in infants with atopic dermatitis and healthy infants: a follow-up from birth to 24 months. Acta Paediatr 2011, 100:e65-e70.
86. Chamlin S.L., Frieden I.J., Williams M.L., Chren M.M. Effects of atopic dermatitis on young American children and their families. Pediatrics 2004, 114:607-611.
87. Camfferman D., Kennedy J.D., Gold M., Simpson C., Lushington K. Sleep and neurocognitive functioning in children with eczema. Int J Psychophysiol 2013, 89:265-272.
88. Chamlin S.L., Mattson C.L., Frieden I.J., Williams M.L., Mancini A.J., Cella D., et al. The price of pruritus: sleep disturbance and cosleeping in atopic dermatitis. Arch Pediatr Adolesc Med 2005, 159:745-750.
89. Dahl R.E., Bernhisel-Broadbent J., Scanlon-Holdford S., Sampson H.A., Lupo M. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995, 149:856-860.
90. Reuveni H., Chapnick G., Tal A., Tarasiuk A. Sleep fragmentation in childrenwith atopic dermatitis. Arch Pediatr Adolesc Med 1999, 153:249-253.
91. Romanos M., Gerlach M., Warnke A., Schmitt J. Association of attention-deficit/hyperactivity disorder and atopic eczema modified by sleep disturbance in a large population-based sample. JEpidemiol Community Health 2010, 64:269-273.
92. Bieber T., Vick K., Folster-Holst R., Belloni-Fortina A., Stadtler G., Worm M., et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 2007, 62:184-189.
93. Leo H.L., Bender B.G., Leung S.B., Tran Z.V., Leung D.Y. Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis. JAllergy Clin Immunol 2004, 114:691-693.
94. Owens J.A., Babcock D., Blumer J., Chervin R., Ferber R., Goetting M., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. JClin Sleep Med 2005, 1:49-59.
95. Mindell J.A., Kuhn B., Lewin D.S., Meltzer L.J., Sadeh A. Behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep 2006, 29:1263-1276.
96. Kelsay K. Management of sleep disturbance associated with atopic dermatitis. JAllergy Clin Immunol 2006, 118:198-201.
97. Chou J.S., LeBovidge J., Timmons K., Elverson W., Morrill J., Schneider L.C. Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy Asthma Proc 2011, 32:377-383.
98. Kupfer J., Gieler U., Diepgen T.L., Fartasch M., Lob-Corzilius T., Ring J., et al. Structured education program improves the coping with atopic dermatitis in children and their parents: a multicenter, randomized controlled trial. JPsychosom Res 2010, 68:353-358.
99. Schmitt J., Apfelbacher C., Chen C.M., Romanos M., Sausenthaler S., Koletzko S., et al. Infant-onset eczema in relation to mental health problems at age 10 years: results from a prospective birth cohort study (German Infant Nutrition Intervention plus). J Allergy Clin Immunol 2010, 125:404-410.
100. Schmitt J., Romanos M., Pfennig A., Leopold K., Meurer M. Psychiatric comorbidity in adult eczema. Br J Dermatol 2009, 161:878-883.
101. Wittkowski A., Richards H.L., Griffiths C.E., Main C.J. The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res 2004, 57:195-200.
102. Yaghmaie P., Koudelka C.W., Simpson E.L. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 2013, 131:428-433.